+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“The global automation in biopharma market is estimated to reach USD 1.23 billion by 2025” says new Visiongain report

22 May 2020
Pharma

Visiongain has launched a new report Automation in Biopharma Industry 2020-2030: Forecasts by Application (Clinical Stage and Drug Discovery Stage) and by Technologies (Automation Technology (DCS, SCADA, PLC, MES, HMI, APC, ERP, LIMS, CRM, CAPA) and Digital Technology (IoT, AI, Digital Twin, AR & VR, Predictive Analytics, Cloud Computing). Plus, Leading Companies Analysis.

The automation in biopharma market is projected to grow at a CAGR of 4.3% in the first half of the forecast period. In 2019, the automation market in biopharmaceutical industry in clinical stage accounted for 62.1% of the automation in biopharmaceutical market. Visiongain estimated that ERP automation in biopharma will be the driver for market growth in the first half of the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

The 142-page Visiongain report provides clear detailed insight into the automation in biopharma market. Discover the key trends and development in the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Automation in biopharma market forecasts from 2020-2030

• This report assesses the application of automation in the biopharma market and gives revenue to 2030

• Provides qualitative analysis and forecast of the submarket by technology for the period 2020-2030:

• Automation Technology
• DCS
• SCADA
• PLC
• MES
• HMI
• APC
• ERP
• LIMS
• CRM
• CAPA

• Digitization Technology
• IoT
• AI
• Digital Twin
• AR & VR
• Predictive Analytics
• Cloud Computing

• Profiles leading companies that will be important in the development of the automation in biopharma market. For each company, developments and outlooks are discussed and companies covered in this chapter include:
• PerkinElmer
• Thermo Fisher Scientific
• Sartorius
• Siemens
• Rockwell
• Zenith (Cognizant)
• RheoSense, Inc.
• Werum
• Emerson
• TetraScience

• Provides qualitative analysis of trends and developments that will affect the automation in biopharma market, from the perspective of biopharmaceutical companies, during the period 2020 to 2030.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Genome Editing Technologies Market Report 2022-2032

The Global Genome Editing Technologies market is estimated to be valued at US$ 4,225.48 million in 2022. The market is projected to reach a market value of US$ 18,570.41 million by 2032. We predict strong revenue growth through to 2032.

02 August 2022

Read

Visiongain Publishes Synthetic Biology Market Report 2022-2032

The global synthetic biology market was valued at US$13.8 billion in 2021 and is projected to grow at a CAGR of 25.52% during the forecast period 2022-2032.

27 July 2022

Read

Visiongain Publishes Biosimilar Monoclonal Antibodies Market Report 2022-2032

The global biosimilar monoclonal antibodies market was valued at US$4,087 million in 2021 and is projected to grow at a CAGR of 23.5% during the forecast period 2022-2032.

25 July 2022

Read

Visiongain Publishes Drug Discovery Services Market Report 2022-2032

The global drug discovery services market is anticipated to be valued at US$14.17 billion in 2022 and is projected to grow at a CAGR of 15.17% during the forecast period 2022-2032.

20 July 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever